Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.
You may also be interested in...
Financings Of The Fortnight Ponders A Post-Euro Financing Environment
Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.
Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line
In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.
Disappointing Provenge Sales Stir Doubts About Demand
Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.